Christopher Cotter

机构：Roche (Switzerland)

发表论文 12 篇 · 总被引 160 次 · h-index 5

代表论文

• Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study (2025 · The Lancet Oncology · 被引 67)
• Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC). (2023 · Journal of Clinical Oncology · 被引 51)
• IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma (2024 · Future Oncology · 被引 26)
• Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy (2025 · Cell Reports Medicine · 被引 8)
• Electrification, telecommunications, and the finance-growth nexus: Evidence from firm-level data (2020 · Energy Economics · 被引 7)
• Meeting enrollment targets in IMbrave152/SKYSCRAPER-14, a global phase 3 study in patients with unresectable hepatocellular carcinoma (HCC). (2025 · Journal of Clinical Oncology · 被引 1)